Treatment of Acute Lymphoblastic Leukemia in T-Cell ALL
T-cell acute lymphoblastic leukemia (T-ALL) is a distinct subtype of ALL arising from early precursors of T cells. The treatment approach in this population is shaped by the subtype's biology and the patient's eligibility for intensive therapy.
Clinical Scenario
T-cell ALL starts in early forms of cells destined to become T cells. In adolescents and young adults with this subtype, intensive pediatric chemotherapy regimens have been associated with improved outcomes compared with standard adult approaches.
Treatment Approach — Overview
Eligible patients typically receive early intensified induction using a multi-drug regimen, with the specific agent combination and consolidation strategy determined by patient fitness and protocol eligibility. More recently, augmentation of intensive pediatric regimens with an additional targeted agent has been shown to further improve outcomes in certain patients.
The complete regimen, sequencing, and dosing details are in the full protocol.
References
- T-cell ALL is a type of ALL that starts in early forms of cells that are to become T cells.
- For adolescents and young adults with T-cell ALL, pediatric, intensive chemotherapy regimens have resulted in improved outcomes.
- Suitable patients should receive early intensified induction with a regimen of four drugs containing vincristine, pegaspargase, an anthracycline (such as daunorubicin or doxorubicin) and a corticosteroid (such as dexamethasone or prednisone), followed by an intensive consolidation regimen.
- Recently, the addition of nelarabine (Arranon®) to intensive pediatric regimens has been shown to further improve disease-free survival for children and young adults with T-cell ALL.
- Patients not suited for a pediatric-intensive regimen should receive multiagent chemotherapy based on the protocol of their treatment center.
View source ↗